{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:13:05Z","timestamp":1780380785126,"version":"3.54.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejphar.2020.173505","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T21:39:44Z","timestamp":1598564384000},"page":"173505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases"],"prefix":"10.1016","volume":"885","author":[{"given":"Maryanne","family":"Covington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Scuron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Juvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Favata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarala","family":"Sarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-biao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Scherle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173505_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12950-017-0175-2","article-title":"Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy","volume":"14","author":"Beattie","year":"2017","journal-title":"J. Inflamm."},{"key":"10.1016\/j.ejphar.2020.173505_bib2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1172\/JCI118861","article-title":"Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses","volume":"98","author":"Berg","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2020.173505_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173505_bib4","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173505_bib5","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.ejphar.2020.173505_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173505_bib7","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2020.173505_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bmc.2018.01.021","article-title":"Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxoprop anenitrile as a JAK1-selective inhibitor","volume":"26","author":"Chough","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173505_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","article-title":"Novel targeted therapies for inflammatory bowel disease","volume":"38","author":"Coskun","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.173505_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/13543784.2018.1492547","article-title":"Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials","volume":"27","author":"D'Amico","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejphar.2020.173505_bib11","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4049\/jimmunol.161.6.3143","article-title":"IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice","volume":"161","author":"Davidson","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.184.1.241","article-title":"T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice","volume":"184","author":"Davidson","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib13","doi-asserted-by":"crossref","DOI":"10.4161\/jkst.23060","article-title":"STAT heterodimers in immunity: a mixed message or a unique signal?","volume":"2","author":"Delgoffe","year":"2013","journal-title":"JAK-STAT"},{"key":"10.1016\/j.ejphar.2020.173505_bib14","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2020.173505_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fendo.2017.00071","article-title":"The Janus kinase (JAK) FERM and SH2 domains: bringing specificity to JAK-receptor interactions","volume":"8","author":"Ferrao","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2020.173505_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib17","doi-asserted-by":"crossref","first-page":"7779","DOI":"10.1073\/pnas.92.17.7779","article-title":"Interleukin 2 signaling involves the phosphorylation of Stat proteins","volume":"92","author":"Frank","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2020.173505_bib18","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib19","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1172\/JCI19836","article-title":"Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis","volume":"113","author":"Fuss","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2020.173505_bib20","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173505_bib21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib22","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2020.173505_bib23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ni.2920","article-title":"TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells","volume":"15","author":"Gerlach","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clim.2017.04.015","article-title":"Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats","volume":"184","author":"Gertel","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib25","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib26","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/j.1460-2075.1995.tb07128.x","article-title":"A major role for the protein tyrosine kinase JAK1 in the JAK\/STAT signal transduction pathway in response to interleukin-6","volume":"14","author":"Guschin","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2020.173505_bib27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1074-7613(02)00453-3","article-title":"Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells","volume":"17","author":"Heller","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2020.173505_bib28","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/rheumatology\/keu430","article-title":"The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels","volume":"54","author":"Isomaki","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2020.173505_bib29","series-title":"Ruxolitinib for the Treatment of Steroid-Refractory Acute GVHD (REACH1): a Multicenter, Open-Label, Phase 2 Trial","author":"Jagasia","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173505_bib30","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejphar.2020.173505_bib31","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (Darwin 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2020.173505_bib32","series-title":"Innovative Medicine","first-page":"131","article-title":"IL-6: a new era for the treatment of autoimmune inflammatory diseases","author":"Kishimoto","year":"2015"},{"key":"10.1016\/j.ejphar.2020.173505_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1254\/jphs.FP0040214","article-title":"Oxazolone-induced colitis in BALB\/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis","volume":"96","author":"Kojima","year":"2004","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.173505_bib34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(93)80068-P","article-title":"Interleukin-10-deficient mice develop chronic enterocolitis","volume":"75","author":"Kuhn","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173505_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2020.173505_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2020.173505_bib37","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib38","first-page":"e1177","article-title":"Crohn's disease and ulcerative colitis show unique cytokine profiles","volume":"9","author":"Nemeth","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2020.173505_bib39","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173505_bib41","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/TP.0b013e3181f24e59","article-title":"CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-gamma pathway","volume":"90","author":"Park","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.ejphar.2020.173505_bib42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.ejphar.2020.173505_bib43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4196\/kjpp.2014.18.4.279","article-title":"A review on chemical-induced inflammatory bowel disease models in rodents","volume":"18","author":"Randhawa","year":"2014","journal-title":"KOREAN J. PHYSIOL. PHARMACOL."},{"key":"10.1016\/j.ejphar.2020.173505_bib44","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173505_bib45","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib46","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bbmt.2017.12.797","article-title":"The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia","volume":"24","author":"Schroeder","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejphar.2020.173505_bib47","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejphar.2020.173505_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2020.173505_bib49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/pr.114.009639","article-title":"Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases","volume":"67","author":"Siebert","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2020.173505_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 Years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejphar.2020.173505_bib51","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173505_bib52","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2020.173505_bib53","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib54","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.270.5237.794","article-title":"Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3","volume":"270","author":"Thomis","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173505_bib55","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.11077","article-title":"Immune regulation in adjuvant-induced arthritis: possible implications for innovative therapeutic strategies in arthritis","volume":"48","author":"Van Eden","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2020.173505_bib56","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib58","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2020.173505_bib59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib60","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173505_bib61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2020.173505_bib62","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173505_bib63","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/rheumatology\/key377","article-title":"Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model","volume":"58","author":"Vidal","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2020.173505_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-3083.2002.01106.x","article-title":"Immune regulation in adjuvant disease and other arthritis models: relevance to pathogenesis of chronic arthritis","volume":"56","author":"Waksman","year":"2002","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ejphar.2020.173505_bib65","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (Darwin 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2020.173505_bib66","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2020.173505_bib67","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/03007995.2018.1551193","article-title":"Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation","volume":"35","author":"Yu","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2020.173505_bib68","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920305975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920305975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:40:20Z","timestamp":1757976020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920305975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":68,"alternative-id":["S0014299920305975"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173505","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"173505"}}